R. Machida

发表

Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial

T. Yoshikawa, Y. Doki, S. Takiguchi, 2020, Gastric Cancer.

TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations

H. Kishima, M. Nagane, K. Ichimura, 2020, Acta Neuropathologica Communications.

Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502

M. Yano, H. Daiko, Ken Kato, 2022, Journal of Gastroenterology.

The association of primary tumor site with acute adverse event and efficacy of definitive chemoradiotherapy for cStage II/III esophageal cancer: an exploratory analysis of JCOG0909

T. Yano, K. Chìn, Ken Kato, 2020, Esophagus.

Prognostic Value of Epithelial Cell Adhesion Molecules in T1‐2N0M0 Glottic Cancer

Y. Nishimura, M. Yoshimura, J. Itami, 2020, The Laryngoscope.

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial

K. Yonemori, Masamichi Takahashi, I. Kinoshita, 2022, BMC cancer.

Perioperative Adriamycin plus ifosfamide vs. gemcitabine plus docetaxel for high-risk soft tissue sarcomas: randomised, phase II/III study JCOG1306

Y. Iwamoto, J. Toguchida, T. Ozaki, 2022, British Journal of Cancer.

Long-term survival of patients with T1bN0M0 esophageal cancer after thoracoscopic esophagectomy using data from JCOG0502: a prospective multicenter trial

M. Yano, H. Daiko, M. Ueno, 2021, Surgical Endoscopy.

Possibility of a risk‐adapted treatment strategy for untreated aggressive adult T‐cell leukaemia‐lymphoma (ATL) based on the ATL prognostic index: a supplementary analysis of the JCOG9801

D. Maruyama, K. Tsukasaki, H. Nagai, 2019, British Journal of Haematology.

Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502

S. Tsunoda, M. Yano, H. Daiko, 2020, Journal of Gastroenterology.

Final analysis of a Multicenter Single-Arm Confirmatory Trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906.

Y. Nishimura, M. Hiraoka, T. Teshima, 2021, Japanese journal of clinical oncology.

Lenvatinib in patients with advanced or metastatic thymic carcinoma (REMORA): a multicentre, phase 2 trial.

Tomoaki Yamada, Y. Ohe, M. Satouchi, 2020, The Lancet. Oncology.

Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials

Toshio Shimizu, A. Shimomura, A. Kuchiba, 2020, ESMO Open.

TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma

T. Maehara, M. Nagane, K. Ichimura, 2021, Acta Neuropathologica.

Results of a randomized phase II/III study comparing perioperative adriamycin plus ifosfamide and gemcitabine plus docetaxel for high-grade soft tissue sarcomas: Japan Clinical Oncology Group study JCOG1306.

Y. Iwamoto, T. Ozaki, K. Asanuma, 2020 .

Single response assessment of transplant-ineligible multiple myeloma: a supplementary analysis of JCOG1105 (JCOG1105S1)

S. Iida, Y. Kagami, M. Kizaki, 2021, Japanese Journal of Clinical Oncology.

Risk factors for surgical site infection and association of surgical site infection with survival of lower rectal cancer patients without clinical lateral pelvic lymph node metastasis (clinical Stage II/III): Analysis of data from JCOG0212

Masaaki Ito, M. Ohue, M. Shiozawa, 2021, Clinical & Experimental Metastasis.

A Single-Arm Confirmatory Study of Definitive Chemoradiotherapy Including Salvage Treatment for Clinical Stage II/III Esophageal Squamous Cell Carcinoma (JCOG0909 Study).

T. Yano, Y. Kitagawa, Ken Kato, 2022, International journal of radiation oncology, biology, physics.

Prognostic value of the Kyoto Prognostic Index in higher-risk diffuse large B-cell lymphomas treated by upfront autologous stem cell transplantation in JCOG0908 trial

Y. Kagami, J. Kuroda, D. Maruyama, 2022, Japanese journal of clinical oncology.

Mortality from extrathymic malignancy after thymic tumour resections: incidences and risk factors.

S. Toyooka, H. Date, K. Kondo, 2019, Interactive cardiovascular and thoracic surgery.

Second malignancy versus recurrence after complete resection of thymoma

M. Sonobe, H. Date, T. Sozu, 2018, Asian cardiovascular & thoracic annals.

Trastuzumab Deruxtecan for Human Epidermal Growth Factor Receptor 2–Expressing Advanced or Recurrent Uterine Carcinosarcoma (NCCH1615): The STATICE Trial

K. Yonemori, K. Ariyoshi, Y. Hirashima, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: a randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

Y. Oda, T. Morii, K. Asanuma, 2023, BMC Cancer.

Randomized controlled Phase III trial to evaluate omentum preserving gastrectomy for patients with advanced gastric cancer (JCOG1711, ROAD-GC).

T. Yoshikawa, H. Katayama, Takanobu Yamada, 2020, Japanese journal of clinical oncology.

A randomized controlled phase III trial of comparing local field with additional prophylactic irradiation in chemoradiotherapy for clinical-T1bN0M0 esophageal cancer:JCOG1904/ARMADILLO study.

Y. Nishimura, Ken Kato, T. Kadota, 2021 .

Topical corticosteroid therapy for facial acneiform eruption due to EGFR inhibitors in metastatic colorectal cancer patients: a randomized controlled trial comparing starting with a very strong or a weak topical corticosteroid (FAEISS study, NCCH1512, colorectal part)

N. Yamazaki, T. Hamaguchi, Y. Kiyohara, 2021, Supportive Care in Cancer.

A multicenter randomized controlled trial of esophagectomy with or without prophylactic supraclavicular node dissection: A phase III trial (JCOG2013, MODERN3).

S. Tsunoda, T. Kamei, Ken Kato, 2023, Journal of Clinical Oncology.

Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.

Y. Hosomi, Y. Ohe, M. Ando, 2023, Lung cancer.

Second primary malignancies in patients with clinical T1bN0 esophageal squamous cell carcinoma after definitive therapies: supplementary analysis of the JCOG trial: JCOG0502

S. Tsunoda, M. Yano, H. Daiko, 2022, Journal of gastroenterology.

A multicenter randomized controlled trial of esophagectomy with or without prophylactic supraclavicular node dissection: a phase 3 trial (JCOG2013, MODERN3)

S. Tsunoda, T. Kamei, Ken Kato, 2023, Japanese Journal of Clinical Oncology.

Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial.

M. Satouchi, Y. Fujisaka, Y. Okuma, 2024, Lung cancer.

Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial

Y. Doki, H. Daiko, H. Miyata, 2024, The Lancet.

Frequency of use and cost in Japan of first-line palliative chemotherapies for recurrent or metastatic squamous cell carcinoma of the head and neck.

Tomofumi Sakagami, R. Machida, K. Wasano, 2024, Japanese journal of clinical oncology.

Real-world treatment trends for patients with advanced prostate cancer and renal cell carcinoma and their cost-a survey in Japan.

R. Machida, K. Sasaki, Takashi Matsumoto, 2024, Japanese journal of clinical oncology.